TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PSORIASIS

Highlights Considering the systemic nature of psoriasis and the high prevalence of cardiovascular diseases among this cohort of patients, it is particularly important to focus on the therapy of these conditions in real clinical practice. Thus, the correct choice of pharmacological strategy and timely adjustment of the ongoing therapy play a crucial role in the course of these diseases. Abstract Background . Currently, psoriasis, as a chronic immune-mediated disease of a multifactorial nature, is one of the most common diseases worldwide. Given the systemic nature of this disease, the level of comorbid pathologies is high, especially those associated with cardiovascular diseases. Aim. To assess the features of the ongoing therapy for psoriasis and CVD in real clinical practice. Methods. The open prospective observational clinical study was conducted. 160 patients diagnosed with mild to severe generalized psoriasis vulgaris constituted the main group, 40 patients were included in the control group. All patients underwent basic clinical and laboratory tests, physical examination with an assessment of body mass index, severity of the disease according to the PASI and DLQI index, psycho-emotional state, and measurement of blood pressure using the Korotkov method. Depending on the age of the patient, the cardiovascular risk (CVR) was assessed using the SCORE2/2OP scale. The therapy used to treat patients with psoriasis and CVD was analyzed. Results. According to the results of the study, patients with high cardiovascular risk (47%) prevail among the patients of the main group, compared with the control group (CG) (30%). There is a high incidence of arterial hypertension (AH) – 34.4% (CG – 22.5%), dyslipidemia – 40% (CG – 5%) (of which only 60% received lipid-lowering therapy), rhythm disturbances – 2% (CG – 1%), CHF – 1% (CG – 1%). Optimal antihypertensive therapy was received by 80% of patients, 20% required hospitalization in the Internal Medicine Department for additional examination and correction of CVD therapy. The use of systemic therapy was quite frequent: 21% received methotrexate, 23% – biological therapy. Conclusion. Thus, in real clinical practice, constant assessment and prevention of CV risk, monitoring of risk factors such as weight, blood pressure, BMI, cholesterol, PASI and DLQI are necessary for a patient-specific, multidisciplinary approach to the treatment of patients with psoriasis and CVD.